Bladder cancer is one of the most common malignancies worldwide and is currently, the second most common urinary malignancy with a high mortality rate and poor prognosis. There are various forms of bladder cancer with urothelial cell carcinoma as the primary histologic subtype, accounting for over 90% of bladder cancer cases. Furthermore, an estimate of 70% of patients are diagnosed with non-muscle-invasive bladder cancer (NMIBC). The remaining are diagnosed with muscle-invasive bladder cancer (MIBC) with which radical cystectomy is the most optimal and standard treatment in combination with neoadjuvant chemotherapy. However, the 5-year overall survival rate is 50% primarily due to the recurrence and metastasis leading to an overall low survival rate following surgical treatment. Therefore, further studies are required to understand how radical cystectomy impacts the survival of bladder cancer patients.
Studies have identified biomarkers involved in bladder cancer including lactate dehydrogenase and hemoglobin as well as a membrane binding enzyme, serum gamma-glutamyltransferase (GGT) which has a demonstrated role in tumor development, influencing the stage of the disease and anti-cancer drug resistance. GGT has also been identified as a prognostic biomarker in various cancers including breast cancer, renal cell carcinoma and prostate cancer. Further studies are required to identify biomarkers and expand our understanding on the molecular mechanisms which influence bladder cancer specifically for bladder cancer patients undergoing radical cystectomy.
This Research Topic aims to generate a discussion regarding the impact and influence of radical cystectomy in bladder cancer patients. We welcome Original Research Articles, Review Articles, Systematic Reviews and Case Reports.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Bladder cancer is one of the most common malignancies worldwide and is currently, the second most common urinary malignancy with a high mortality rate and poor prognosis. There are various forms of bladder cancer with urothelial cell carcinoma as the primary histologic subtype, accounting for over 90% of bladder cancer cases. Furthermore, an estimate of 70% of patients are diagnosed with non-muscle-invasive bladder cancer (NMIBC). The remaining are diagnosed with muscle-invasive bladder cancer (MIBC) with which radical cystectomy is the most optimal and standard treatment in combination with neoadjuvant chemotherapy. However, the 5-year overall survival rate is 50% primarily due to the recurrence and metastasis leading to an overall low survival rate following surgical treatment. Therefore, further studies are required to understand how radical cystectomy impacts the survival of bladder cancer patients.
Studies have identified biomarkers involved in bladder cancer including lactate dehydrogenase and hemoglobin as well as a membrane binding enzyme, serum gamma-glutamyltransferase (GGT) which has a demonstrated role in tumor development, influencing the stage of the disease and anti-cancer drug resistance. GGT has also been identified as a prognostic biomarker in various cancers including breast cancer, renal cell carcinoma and prostate cancer. Further studies are required to identify biomarkers and expand our understanding on the molecular mechanisms which influence bladder cancer specifically for bladder cancer patients undergoing radical cystectomy.
This Research Topic aims to generate a discussion regarding the impact and influence of radical cystectomy in bladder cancer patients. We welcome Original Research Articles, Review Articles, Systematic Reviews and Case Reports.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
